Biologics & Biosimilars

Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

March 12, 2020 • By Thomas R. Collins

Clinicians Discuss Current & Future Rheumatoid Arthritis Approaches

March 12, 2020 • By Mike Fillon

FDA Update: New Drug Approvals, New & Expanded Indications, & More

March 12, 2020 • By Susan Bernstein

Remembering Etanercept & the Advent of the Biologic Era

February 10, 2020 • By Robert S. Katz, MD

Biologic Spending & Price Trends

January 28, 2020 • By Arthritis & Rheumatology

Canada & E.U. Approve Upadacitinib for RA

January 28, 2020 • By Michele B. Kaufman, PharmD, BCGP

EU Approves Remsima SC, a Biosimilar to Infliximab

January 2, 2020 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Amgen’s Infliximab Biosimilar Treatment

December 10, 2019 • By Reuters Staff

Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA

November 25, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

November 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
31
Next Page »